Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Those baying for blood need to wait a bit longer .
LAST AGM "The Annual General Meeting will be held on Wednesday, 28 June 2023 at 10.30 a.m. BST at The Royal Society of Medicine, 1 Wimpole Street, Westminster, London W1G 0AE (the "Venue").
Nice stock to hold : Nationwide just started early days yet -
"#RNS Trading update for the year ending March 31 2024: Trading in line with market forecasts and management expectations.
Disclosing to the market we have now launched with 4 US Insurers in 4 US states:
Ohio,
New York,
New Jersey
and Washington
Positive feedback and excellent results from US launches has underlined the potential for LeakBot in the USA with both new partners, and potential for multi state rollouts with existing partners"
Sorry Hurst10 --my version automatically translates .
Pertinent ADC bits :
"3. Finding partners who can share the future of ADC through open collaboration
3. ADC secures a unique position as the food of the future
ADC stands for Antibody Drug Conjugate, which translates to 'antibody-drug conjugate'. It is characterized by attaching an antibody that recognizes the antigen protein of a specific cancer cell to the drug, and it attacks only the target cancer cells by connecting the antibody drug and the cytotoxic drug with a *linker. It has the advantage of increasing the therapeutic effect and minimizing side effects, so it is in the spotlight as a next-generation anticancer drug.
Along with the expansion of the ADC market, there is also a growing movement to secure pipelines. Daewoong Pharmaceuticals is also considering domestic and foreign ADC companies that will grow together through cooperation.
It is no exaggeration to say that Daewoong Pharmaceutical's R&D competitiveness began with various new drug collaborations. In order to continue the reputation of Korea's first bio drug, botulinum toxin, gastroesophageal reflux disease treatment, type 2 diabetes drug, and pulmonary fibrosis drug, the company is considering cooperation with companies that have new ADC drugs and conjugates.
In particular, Daewoong Pharmaceutical's New Drug Center, which is implementing smart and rapid R&D 'smart collaboration', is building various evaluation platforms for the development of treatments for anti-cancer, autoimmune, fibrosis, and metabolic diseases. First, based on the experience and master plan throughout the entire cycle from non-clinical to product approval, we actively share quality control, documentation, and CMC capabilities for R&D and manufacturing processes with partners. In addition, it also seeks to co-exist with startups by supporting a network of clinical KOLs (Key Opinion Leaders). As such, Daewoong Pharmaceutical's New Drug Center is always looking forward to meeting partners who will rewrite the future of ADC with an open mind.
*CMC: Chemistry, Manufacturing, and Control, which refers to the process development and quality control areas of making pharmaceuticals.
So far, we have looked at the trends in the pharmaceutical and bio industries announced at JPM 2024, and we have looked at Daewoong Pharmaceutical's focus on AI drug development, GLP-1 obesity treatment, and aromatic-drug conjugates (ADCs). Daewoong Pharmaceutical, which has solidified its position as a trend-leading pharmaceutical company, will continue its journey to become a global big pharma."
Good Morning
Note Daewoong ADC comments . ( Not related to existing Avacta JV stem cells @AffyXell Therapeutics Co.,Ltd. )
However might be a future opportunity for co·operation , anyway like the way Daewoong communicate .
"JPM 2024 was an opportunity to confirm that the biotech and pharmaceutical industries are still keenly interested in ADCs. In fact, in 2023, major pharmaceutical companies have made large investments to preempt the ADC market. This is a clear example of how many companies are choosing ADC as the food of the future.
The future of ADC is bright. This is evidenced by the projection that ADCs will account for more than 8% of the $375 billion global cancer market by $375 billion by 2028. The global ADC market is also expected to grow from $9.78 billion in 2023 to $19.8 billion by 2028, growing at a CAGR of 15.2%."
https://newsroom.daewoong.co.kr/archives/category/news
https://newsroom.daewoong.co.kr/archives/23405
Good Morning Weather very nice in Portugal - Diagnostics getting on with the day job - Therapeutics still in preparation for take- off : SP watchers looking for pennies - shareholders just sit back & relax .
------------------
Note : Coris/LD working together
Launch Diagnostics France SASLaunch Diagnostics France SAS
216 followers216 followers
2d • 2d •
Follow
Launch Diagnostics France SAS : Distributeur exclusif des produits de la gamme RESIST de Coris Bioconcept en France
hashtag#antibioresistance hashtag#AMR hashtag#RESIST hashtag#BMR hashtag#Testsrapides
Rate this translation
Launch Diagnostics France SAS: Exclusive distributor of Coris Bioconcept's RESIST range products in France
hashtag#antibioresistance hashtag#AMR hashtag#RESIST hashtag#BMR hashtag#Testsrapides
-----------
LD man in Germany getting to know the team
"Lena KastlLena Kastl
• 3rd+• 3rd+
Managing Director bei Launch Diagnostics Deutschland GmbHManaging Director bei Launch Diagnostics Deutschland GmbH
4d • 4d •
Follow
Get in touch and meet newly established Launch Diagnostics Deutschland GmbH at ECCMID in Barcelona!
https://www.linkedin.com/in/davidswilson/recent-activity/all/
Not a very cheery board today . I prefer to concentrate on the positives . .
Avacta managenent great foresight to obtain control of the science technology & hold the IP licences . As has been ably demonstrated recently in presentations the science works . Will eventually deliver substantial investment returns . Then the same folks bad mouthing the managenent today will then be singing their praises and we will all be very happy .
"Avacta commenced a two-weekly dosing safety study in the US on the basis that this is likely to lead to better efficacy. Three patients have now been dosed in cohort 1 (160 mg/m2) of the two-weekly dose escalation study in the US and Avacta has received regulatory and ethics approval to open sites in the UK in the two-weekly arm. Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April."
"A company’s IP strategy should manage and protect its intellectual property in a way that aligns with its overall business goals and strategy, ensuring that the intellectual property is being effectively protected, optimized (for value), and monetized (when possible), maximizing the value of the protected assets and their potential commercial benefits.
https://www.excedr.com/resources/intellectual-property-strategy-for-biotechs
Note :
"CORIS BIOCONCEPTCORIS BIOCONCEPT
2,555 followers2,555 followers
3d • 3d •
Follow
𝗘𝗖𝗖𝗠𝗜𝗗 𝟮𝟬𝟮𝟰 is approaching fast! 🚀
The congress will be held this year in the wonderful city of Barcelona 🇪🇸 from April 27th to 30th. We can't wait to be there!
Come and meet us at booth F-10 to discuss rapid tests and AntiMicrobial Resistance. 🦠🧫
https://www.eccmid.org/#
Visit our website for more information: https://www.corisbio.com
Fight #AMR together
#ECCMID2024 #Innovation #RapidTests #GlobalHealth #RaiseAwareness"
Whatever the logic , it would make sense for Avacta diagnostics to be a going cencern might help the future sale proceeds .
Coris purchase
Dr Alastair Smith, Chief Executive Officer, Avacta Group plc, commented:
“The acquisition of Coris provides the Group with a broad, professional-use rapid test product portfolio. Complementing the acquisition of Launch Diagnostics last year, the Acquisition represents an important step in establishing a full-spectrum in-vitro diagnostics business covering centralised, pathology laboratory diagnostics, as well as decentralised, point-of-care testing solutions outside the hospital setting.
“Antibiotic resistance is a major global challenge and we strongly believe that the market for antimicrobial resistance (“AMR”) testing is one with good future growth prospects. We are particularly pleased, therefore, to have added an AMR product portfolio to the Group with this acquisition.
“With this acquisition, our Diagnostics division has taken another important step towards realising its mission to support healthcare professionals and broaden access to high quality diagnostics.”
--------------
"The global antimicrobial resistance diagnostics market size was valued at USD 3.9 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2030. High disease burden from pathogens such as streptococcus pneumonia, MRSA, C. difficile infections, and others coupled with the surge in the incidence of Antimicrobial Resistance (AMR) infections are the major factors fueling the market growth."
LD distribute products for 40 + manufacturers - profitable business aquisition for the Avacta Group , be interesting to see the next accounts .
--------------------------------------
https://en.vircell.com/
https://www.launchdiagnostics.com/
---------------------
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,558 followers1,558 followers
1d • 1d •
Ensuring Quality in Molecular Testing: Introducing Vircell's Amplirun and Amplirun Total Ranges
Quality assurance is the cornerstone of every testing laboratory, and third-party molecular controls play a key role in this process. Vircell's Amplirun and Amplirun Total ranges offer comprehensive solutions for various applications:
🔹 Amplirun: With over 140 single-target controls, Amplirun is perfect for daily use, enabling precise determination of parameters like Limit of Detection (LoD). Plus, with concentrations ranging from 12500 to 20000 copies/µl, accuracy is guaranteed.
🔹 Amplirun Total: Featuring 20 full-process molecular controls, Amplirun Total sets the standard with clinically appropriate matrices that mimic human samples. These controls are multiplexed for an efficient Quality Control (QC) workflow.
Whether it's routine daily testing, batch acceptance, or assay verification, Vircell's solutions provide the reliability and accuracy labs need. Elevate your laboratory's quality assurance with Amplirun and Amplirun Total from Vircell.
https://lnkd.in/e2UMvkF4
https://lnkd.in/enyyBKZj
---------
P.S. Thankfully @ beinthelead has me blocked so will not be having a meltdown .
Courtesy of @Ophidian18 twitter ; Thought this worth sharing - Avacta science offers something different "No other system is whole Tumour targeting"
-----------------------------------
"I want to just unpick something which #AVCT have said a couple of times recently both CC and last night AS as I'm not sure it has really landed for everyone.
And that is around the Peptide Drug Conjugate platform (pre|CISION) being the ONLY system that targets the Tumour
9:41 AM · Apr 11, 2024
·
1,258
Views
Replying to @Ophidian18
No file chosen
Ophidian
@Ophidian18
·
1h
Sure there are now more than a dozen registered ADCs (and dozens more in development) that target a specific antigen, but that antigen is usually ONLY present on a specific cell type - typically the cancer cell and that is NOT the Tumour the Tumour is unfortunately much more.
Ophidian
@Ophidian18
·
1h
FAP is expressed in CAFs as well as on the cell surface of some cancerous cells. Because the Peptide Drug Conjugate system is cleaved rather than binding that means that through the bystander effect, pre|CISION provides a mechanism to target the whole Tumour
Ophidian
@Ophidian18
·
1h
As well as providing a highly specific and discriminating way to deliver a cytotoxic warhead to the Tumour the PDC could also land an ADC to specifically target cancerous cells right in the Tumour where it is needed sparing other tissues. No other system is whole Tumour targeting"
good morning appreciate dr smith taking the time to explain the science and give thoughtful answers .
for those that continue to **** off company management that is of course your prerogative . will not change anything as frankly zero chance the founder of the company will be removed .
dr smith has the ip under control , no doubt in my mind shareholders will eventually be rewarded . obviously not as quick as some of you expected sorry about that . anyway we start again. better in my view stick with the science & support the avacta team & take responsibility for your own investment decisions .
have a nice day .
Avacta well funded , can now continue with clinical plans , no reason to think they will not succeed . Quite exceptional for Avacta to have presented such comprehensive data for a partially completed phase one trial. Visible evidence that the POC technology treatment works . Super safety & amazing signs of early efficancy which is tremedous news for those pre-treated patients . Going forward . Looks like more frequent two weekly dosing will provide better cumulative exposure for efficancy not a single max dose. So not long before those results then ready for phase 2 next stage . Re-Rate .
Avacta already have a major pharma :Lilly have a licence (Point B ) " The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals."
We wait & see who else decides to get involved , many other cancer drugs could be added , means more licences + opportunity to provide ADC comparable treatments - huge global market awaits .
Plus Avacta have other JV assets & diagnostics . Anyway one thing for sure certainly a marathon not a sprint for all parties involved . Look forward to the day ( -current paper deficit -53.31% --- the other way around .)
Good luck everyone
Capital Markets -just for AVA6000
"The results confirm the positive progress being made in the clinical testing of AVA6000 and support the company’s above target fundraise of £31.1m completed in March which will fund the dose expansion and Phase 2 efficacy studies for AVA6000 as well as progress the company’s drug pipeline more generally, including its AVA3996 asset. If Phase 2 testing enables commercial sales to start from 2026/27, we calculate a value for AVA6000 alone at 89p rising to 182p on the implementation of Phase 2 testing. "
https://avacta.com/investors/research-analyst
Thanks : https://twitter.com/udai_banerji/status/1777778199289581619
udaibanerji
@udai_banerji
New frontiers in exploiting stroma for therapy. FAP directed precision medicine. Phase I of AVA600 showing tolerability, plasmas/tumour PK and clinical proof of concept response in FAP high tumours. Abstract CT188 #AACR2024
@ICR_London
@royalmarsdenNHS
@ECMC_UK
Not quite the stampede yet but business discussions always in private .
"If you are attending #AACR24 stop by to see our poster presentation today 9:00 AM – 12:30 PM (PDT)."
https://twitter.com/avacta/status/1777731660416524727
FYI ; CC explains https://avacta.wistia.com/medias/b74537ezmn
Https://avacta.com/wp-content/uploads/2024/04/Banerji-et-al-2024-AVA6000-AACR_final.pdf
AACR -ADC sessions very busy :
Apparently "Easier to get a ticket for a Taylor Swift concert than to find a seat at the #AACR24 Next Generation ADC session!" wait to they hear about : https://avacta.com/precision/precision-drug-conjugate-pdc/
"https://twitter.com/PTarantinoMD/status/1777071782010474563/photo/1